Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why MiMedx Group Inc (MDXG) Shares Imploded

Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.

What: Shares of MiMedx Group Inc (NASDAQ:MDXG), a manufacturer of patented regenerative biomaterial products (in essence, products designed to treat inflammation and help wounds heal), were eviscerated, falling as much as 70% at one point before recovering half of its losses after it announced the receipt of an untitled letter from the Food and Drug Administration alleging it does not possess the proper licensing to manufacture certain products.

MiMedx Group Inc (NASDAQ:MDXG)

So what: According to the FDA’s untitled letter (note, an untitled letter is a notice of violation(s), but does not meet the threshold of a warning letter), because some of the products handled by MiMedx Group Inc (NASDAQ:MDXG) have been treated with a micronization process, they should be treated as drugs and therefore licensed by the FDA. Without the proper licenses, the assumption would be that MiMedx Group Inc (NASDAQ:MDXG) is unlawfully manufacturing some of its products.

Now what: It did not take long for MiMedx Group Inc (NASDAQ:MDXG)’s management team to fire back, with COO and President Bill Taylor noting his surprise at the receipt of the letter and the company standing behind its full-year revenue guidance for 2013 and 2014. Although MiMedx’s management does believe it’s done everything to meet the pre-set guidelines, CEO Parker Petit noted that the company can alter its production to meet its revenue goals. MiMedx Group Inc (NASDAQ:MDXG) plans to meet with the FDA to determine the next course of action.

As of now this is a gigantic mess and the yellow caution tape should be flowing until further notice. On one hand, if MiMedx is found to be in the clear, then it could very easily recoup much of today’s losses. Conversely, the confirmation of the receipt of an untitled letter solidifies the seriousness of these allegations and poses the potential to put a serious dent in MiMedx Group Inc (NASDAQ:MDXG)’s revenue growth. Feel free to add it to your Watchlist, but I’d suggest keeping a distance in all walks from this stock until further notice.

The article Why MiMedx Group Shares Imploded originally appeared on and is written by Sean Williams.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!